NDA 220449 · Boehringer Ingelheim
Jascayd
Nerandomilast · Oral
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 19, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
35
11 Phase 3, 7 recruiting
FAERS reports
1,737
635 serious, 175 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2025 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Breakthrough therapyOrphanLabelLetterLetter
2 products under this application
- JASCAYD · NERANDOMILAST 18MG · TABLET, ORAL · Prescription
- JASCAYD · NERANDOMILAST 9MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nerandomilast" as an intervention, any sponsor and status, largest first.
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06238622 · 1,666 participants · Start Sep 26, 2024 · Primary completion Apr 28, 2027
Drug: Nerandomilast · For: Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 375 sites in all
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05321082 · 1,178 participants · Start Nov 16, 2022 · Primary completion Dec 18, 2024
Drug: BI 1015550; Placebo · For: Lung Diseases, Interstitial
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 400 sites in all
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05321069 · 1,177 participants · Start Oct 6, 2022 · Primary completion Aug 16, 2024
Drug: BI 1015550; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 334 sites in all
- FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07540988 · 466 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 5, 2028
Drug: Nerandomilast; Placebo matching nerandomilast · For: Interstitial Lung Diseases
Sites: Birmingham, Alabama; Los Angeles, California; Newport Beach, California · 162 sites in all
- A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07497087 · 448 participants (planned) · Start Jul 27, 2026 · Primary completion Feb 26, 2030
Drug: Placebo matching nerandomilast formulation 1; Placebo matching nerandomilast formulation 2 and 2 more · For: Systemic Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 248 sites in all
- A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06806592 · 414 participants · Start Sep 13, 2025 · Primary completion Apr 15, 2027
Drug: Nerandomilast; Placebo matching nerandomilast · For: Interstitial Lung Diseases; Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 153 sites in all
- Platform Clinical Study for Conquering SclerodermaPivotal-lookingRecruiting
Scleroderma Research Foundation, Inc.Academic, hospital or other
NCT06195072 · 400 participants (planned) · Start Apr 15, 2024 · Primary completion Nov 2026
Drug: Amlitelimab; BI 1015550 (Nerandomilast) and 1 more · For: Interstitial Lung Disease Due to Systemic Disease; Scleroderma
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 34 sites in all
- A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory MyopathiesPivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07789015 · 270 participants (planned) · Start Dec 14, 2026 · Primary completion Mar 21, 2030
Drug: Placebo; Nerandomilast · For: Idiopathic Inflammatory Myopathies
Sites: Scottsdale, Arizona; Irvine, California; Los Angeles, California · 160 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea488
- nausea196
- fatigue192
- headache184
- dyspnoea183
- cough164
- dizziness150
- decreased appetite117
- death101
- back pain89
- weight decreased87
- pneumonia66
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 111 |
| 2026 | 1,623 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Maher TM, Assassi S, Azuma A, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Wijsenbeek MS, Assassi S, Azuma A, et al. · Eur Respir J 2026 · Randomized Controlled Trial, Multicenter Study
- Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Shahzad H, Afzaal U, Saleem F, et al. · Clin Respir J 2026 · Systematic Review, Meta-Analysis
- Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.
Oldham JM, Azuma A, Kreuter M, et al. · Am J Respir Crit Care Med 2026 · Randomized Controlled Trial, Multicenter Study
- Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers.
Jappar D, Wu J, Burkard U, et al. · Eur J Drug Metab Pharmacokinet 2026 · Randomized Controlled Trial
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.